Horizon Therapeutics PLC (NASDAQ:HZNP) – Investment analysts at Piper Sandler decreased their Q1 2020 earnings estimates for Horizon Therapeutics in a report issued on Tuesday, February 11th. Piper Sandler analyst D. Amsellem now expects that the biopharmaceutical company will earn $0.34 per share for the quarter, down from their prior estimate of $0.36. Piper Sandler also issued estimates for Horizon Therapeutics’ Q2 2020 earnings at $0.46 EPS, Q3 2020 earnings at $0.55 EPS, Q4 2020 earnings at $0.64 EPS, FY2020 earnings at $1.99 EPS, Q1 2021 earnings at $0.58 EPS, Q2 2021 earnings at $0.71 EPS, Q3 2021 earnings at $0.78 EPS, Q4 2021 earnings at $0.84 EPS, FY2021 earnings at $2.91 EPS, FY2022 earnings at $3.59 EPS and FY2023 earnings at $3.89 EPS.
Several other equities analysts have also recently issued reports on HZNP. Piper Jaffray Companies reiterated a “buy” rating and set a $49.00 price target (up previously from $36.00) on shares of Horizon Therapeutics in a research report on Tuesday, December 24th. Morgan Stanley boosted their price target on shares of Horizon Therapeutics from $32.00 to $38.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. BMO Capital Markets boosted their price target on shares of Horizon Therapeutics from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Goldman Sachs Group initiated coverage on shares of Horizon Therapeutics in a research report on Wednesday, January 8th. They set a “neutral” rating and a $35.00 price target on the stock. Finally, JMP Securities boosted their price target on shares of Horizon Therapeutics to and gave the company an “outperform” rating in a research report on Tuesday, January 14th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $37.57.
In related news, EVP Brian K. Beeler sold 9,969 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $32.51, for a total transaction of $324,092.19. Following the sale, the executive vice president now owns 89,633 shares of the company’s stock, valued at $2,913,968.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Timothy P. Walbert sold 84,886 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $35.57, for a total transaction of $3,019,395.02. Following the sale, the chief executive officer now directly owns 987,991 shares in the company, valued at approximately $35,142,839.87. The disclosure for this sale can be found here. Insiders have sold 114,413 shares of company stock worth $4,039,099 in the last three months. 4.10% of the stock is currently owned by insiders.
Large investors have recently bought and sold shares of the stock. Bank of Montreal Can lifted its stake in shares of Horizon Therapeutics by 6,460.8% in the fourth quarter. Bank of Montreal Can now owns 1,089,624 shares of the biopharmaceutical company’s stock worth $39,444,000 after buying an additional 1,073,016 shares in the last quarter. Rhenman & Partners Asset Management AB bought a new position in shares of Horizon Therapeutics in the third quarter worth approximately $27,911,000. Renaissance Technologies LLC lifted its stake in shares of Horizon Therapeutics by 8.0% in the fourth quarter. Renaissance Technologies LLC now owns 10,100,675 shares of the biopharmaceutical company’s stock worth $365,644,000 after buying an additional 750,100 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Horizon Therapeutics by 82.8% in the fourth quarter. Victory Capital Management Inc. now owns 1,555,816 shares of the biopharmaceutical company’s stock worth $56,320,000 after buying an additional 704,566 shares in the last quarter. Finally, William Blair Investment Management LLC lifted its stake in shares of Horizon Therapeutics by 6.2% in the fourth quarter. William Blair Investment Management LLC now owns 8,855,490 shares of the biopharmaceutical company’s stock worth $320,569,000 after buying an additional 515,049 shares in the last quarter. 88.51% of the stock is currently owned by institutional investors and hedge funds.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Further Reading: Why does a company issue an IPO?
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.